We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Open Biosystems and Abcam Announce Partnership to Match Antibodies with Genetic Content

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Open Biosystems and Abcam Announce Partnership to Match Antibodies with Genetic Content"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Open Biosystems, Inc. and Abcam, Plc., announced that they have entered into an agreement under which Open Biosystems will sell Abcam's primary antibodies alongside Open's libraries of cDNA, ORF and shRNA clones. The agreement creates the world's most extensive resource of genetic content for the analysis of gene function.

Customers will be able to use the advanced gene search tool at Open's website to query by gene symbol or accession to bring up an index of all of the matched content available to study a gene. Matched products will be shipped together within 48 hours of order receipt.

Matt Baker, Executive VP of Business Development at Open, said, "Open Biosystems continues to enhance the value of genetic content available for academic and commercial scientists. The agreement with Abcam further enables researchers to have access to a comprehensive solution for functional gene analysis expressing a gene, knocking down a gene and detecting the gene product all from one provider."

Jonathan Milner, CEO of Abcam said, "We are delighted to sign this agreement with Open Biosystems. Abcam is recognized in the marketplace for the quality of our products and we are happy to provide Open Biosystems with a selection of our products for distribution alongside their comprehensive range of gene content analysis components. We are enthusiastic to be working alongside Open Biosystems, and I believe it will allow both companies to expand in this exciting part of the market.